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Abstract
Background: Treatment options for overactive bladder (OAB) with urinary urge incontinence (UUI)
refractory to oral antimuscarinics include: botulinum toxin type A (BoNTA), sacral neuromodulation
(SNM), and augmentation cystoplasty (AC). A standard treatment success metric that can be used in both
clinical and economic evaluations of the above interventions has not emerged. Our objective was to
conduct a literature review and synthesis of published measures of treatment success for OAB with UUI
interventions and to identify a treatment success outcome.
Methods: We performed a literature review of primary studies that used a definition of treatment
success in the OAB with UUI population receiving BoNTA, SNM, or AC. The recommended success
outcome was compared to generic and disease-specific health-related quality-of-life (HRQoL) measures
using data from a BoNTA treatment study of neurogenic incontinent patients.
Results: Across all interventions, success outcomes included: complete continence (n = 23, 44%), ≥ 50%
improvement in incontinence episodes (n = 16, 31%), and subjective improvement (n = 13, 25%). We
recommend the OAB with UUI treatment success outcome of ≥ 50% improvement in incontinence
episodes from baseline. Using data from a neurogenic BoNTA treatment study, the average change in the
Incontinence Quality of Life questionnaire was 8.8 (95% CI: -4.7, 22.3) higher for those that succeeded (N
= 25) versus those that failed (N = 26). The average change in the SF-6D preference score was 0.07 (95%
CI: 0.02, 0.12) higher for those that succeeded versus those that failed.
Conclusion: A treatment success definition that encompasses the many components of underlying OAB
with UUI symptoms is currently not practical as a consequence of difficulties in measuring urgency. The
treatment success outcome of ≥ 50% improvement in incontinence episodes was associated with a
clinically meaningful improvement in disease-specific HRQoL for those with neurogenic OAB with UUI.
The recommended success definition is less restrictive than a measure such as complete continence but
includes patients who are satisfied with treatment and experience meaningful improvement in symptoms.
A standardized measure of treatment success will be useful in clinical and health economic applications.
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Background
Overactive bladder disease (OAB) is defined by the Stand-
ardization Subcommittee of the International Continence
Society (ICS) as urinary urgency, with or without urinary
incontinence, usually with frequency and nocturia, with
no proven infection or other obvious pathology [1]. As
part of the National Overactive Bladder Evaluation
(NOBLE) program: 16.5% of the USA population (16% of
men and 16.9% of women) over 18 years of age had
symptoms consistent with OAB [2]. This translates into
approximately 34 million symptomatic people in the USA
alone. Of the 16.5% of the adult population with symp-
toms consistent with OAB, 37.2% were characterized as
having OAB with urinary urge incontinence (UUI) [2].
OAB significantly impacts heath related quality of life [3]
and is associated with comorbidities such as increased risk
of falls and fractures, increased urinary tract and skin
infections, sleep disturbances, depression, and decreased
sexual health [4,5]. The economic impact of OAB is con-
siderable given its estimated attributable cost of $12.02
billion in the USA for the year 2000 [6].
Depending on severity and etiology, initial treatment of
OAB is characterized by behavioral modification (timed
voiding, bladder training, pelvic floor exercises, etc) and
antimuscarinic drugs. Behavioral interventions for treat-
ing OAB such as bladder training are often the first line
therapy for mild symptoms of urge, frequency, and/or
incontinence. Bladder training involves patient educa-
tion, scheduled voiding, and positive reinforcement.
Other behavioral interventions include pelvic floor exer-
cises (PFE) and biofeedback. PFEs are thought to inhibit
spontaneous bladder contractions and also increase blad-
der outlet resistance to result in reduced leakage and
increased voiding intervals. Biofeedback is a way of noti-
fying the patient when certain physiologic events are
occurring (e.g. unstable bladder contraction or proper PFE
contraction).
In a Cochrane review on bladder training, treatment out-
comes consisted of patient's global observations (percep-
tion of a cure or improvement in their incontinence),
quantification of symptoms (adverse events, number of
incontinence episodes, number of micturitions in day and
night), and quality of life (Incontinence Impact Question-
naire and SF-36) [7]. Outcomes in PFEs and biofeedback
include the quantification of symptom domains, and uro-
dynamic outcomes [8].
Most urinary incontinent patients initiate treatment with
antimuscarinic therapy. Six antimuscarinic drugs are cur-
rently marketed worldwide for the treatment of OAB: oxy-
butynin, tolterodine, propiverine, trospium, darifenacin,
and solifenacin [9]. Each product has demonstrated effi-
cacy in treating OAB symptoms but includes such com-
mon adverse events as dry mouth, constipation,
headache, and blurred vision. In a review of antimus-
carinic drugs versus placebo, Nabi and colleagues found
that there was a lack of consistency in the types of out-
comes reported by trialists [10]. Heterogeneity in urinary
incontinence and other clinical characteristics in various
OAB trial patient populations may partly describe such
differences. We attempted to reduce clinical characteristic
heterogeneity by focusing on treatment success defini-
tions in populations that have failed antimuscarinic ther-
apy.
If patients fail oral drug (antimuscarinic) therapy, more
invasive interventions are available. Approved implanta-
ble neurostimulator devices have been used with some
success, sacral neuromodulation (SNM), but are costly
[11]. Surgical options such as augmentation cystoplasty
(AC), and neobladder construction, or urinary diversion
are available, but are limited to those that have failed the
previous mentioned techniques due to elevated risk pro-
file and complexity of the surgeries. Although still in
phase II and phase III studies, botulinum toxin type A
(BoNTA) is emerging as a potential treatment option for
idiopathic and neurogenic OAB with urinary urge incon-
tinence, respectively [12].
Clinicians, payers, and other health care decision makers
all have interest in determining whether or not a patient
management strategy is successful. In part due to patient
heterogeneity, interventions that are indicated for the
management of OAB with UUI lack standardization in the
measurement of treatment response or treatment success.
A consistent and validated treatment success metric would
allow for more efficient use of healthcare resources, facil-
itating the clinician and patient to more transparently
weigh the risk-benefit profile of treatment alternatives. A
standardized success outcome would also permit more
consistent value for money assessments across and
beyond OAB interventions.
The objectives of this research are to review common
treatment success outcomes used in both idiopathic and
neurogenic OAB with UUI, focusing on the different
antimuscarinic refractory intervention classes and to rec-
ommend a measure of treatment success for clinical
research and health economic applications.
Methods
Review Methodology
We performed a review of studies that published treat-
ment success outcomes for OAB patients with UUI refrac-
tory to antimuscarinic therapy. A computerized search of
PubMed and the grey literature including the Google
search engine was conducted for studies published
between 1998 and 2008. Studies were also obtained fromBMC Urology 2009, 9:18 http://www.biomedcentral.com/1471-2490/9/18
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references of published reviews and accepted studies.
Studies published prior to 1998 were not included in part
due to the lack of appropriate outcome development.
Search terms used for retrieval of botulinum toxin studies
were "botulinum A toxin overactive bladder," sacral neu-
romodulation were "sacral neuromodulation overactive
bladder," and surgical treatment studies were "augmenta-
tion overactive bladder OR clam augmentation." Abstracts
were excluded from this literature review if they were not
published in English, published as a review, used botuli-
num toxin type B as treatment, was a dose determining or
safety study, included a patient population that did not
have urinary urge incontinence, was conducted in animals
or in pediatrics, or conducted as a case series. In addition,
we required included studies to report a measure of treat-
ment success in terms of the proportion of the study pop-
ulation. Data extracted from the studies included; study
design, patient characteristics, intervention, follow up
time, definition of success, and proportion of participants
that succeeded. In our analysis we summarized by defini-
tion of treatment success, the proportion of patients that
succeeded the intervention of study.
Treatment Success Association
We selected the best candidate for a treatment success def-
inition based in part on its emphasis and use as reported
in the literature. We associated this candidate definition
using patient level data from a clinical study of 59 patients
with neurogenic urinary incontinence [13]. We investi-
gated the relationship between the identified/recom-
mended treatment success measure and both generic and
disease-specific health-related quality of life (HRQoL)
outcomes. We used the Incontinence Quality of Life Ques-
tionnaire (I-QOL) [14] as an estimate of the disease-spe-
cific HRQoL and preference scores from the SF-6D as an
estimate of generic HRQoL. We followed the methods
outlined by Brazier et al to convert existing SF-36 data into
preference scores (range 0-1) [15]. The I-QOL is an incon-
tinence-specific measure that has shown high levels of
validity and reliability in stress incontinence, overactive
bladder and neurogenic detrusor overactivity [14,16]. The
I-QOL consists of 22 items that fall within three domains:
avoidance and limiting behavior; psychosocial impacts;
and social embarrassment. For each item, subjects assign
a value on a 5-point Likert scale from 1 (extremely) to 5
(not at all). The total scale score for all 22-items is trans-
formed to a 0 (extreme incontinence problems) to 100
(no incontinence problems) range.
We performed two-sample t-tests assuming equal vari-
ances to estimate the mean difference in the I-QOL and
SF-6D change scores for treatment success versus treat-
ment failure patients. The minimal important difference
(MID) observed for the I-QOL instrument was a change in
the total score of at least 6.3 for patients with stress urinary
incontinence [17]. We used the MID as a benchmark to
determine if the average difference observed in the I-QOL
was clinically meaningful. Although the Schurch et al.
study intervention was BoNTA compared to placebo, we
did not adjust for treatment assignment or any other base-
line characteristics in the validation of the treatment suc-
cess outcome.
Results
Botulinum Toxin Type A (BoNTA)
There is an emerging body of evidence in support of the
efficacy and safety of using BoNTA in OAB [12]. A review
by Duthie and colleagues of randomized or quasi-rand-
omized controlled trials of BoNTA found similar out-
comes reported as in the antimuscarinic therapy reviews
[18]. Changes in incontinence rates were the most fre-
quently reported efficacy outcome followed by urinary
frequency, health-related quality of life, and urodynamic
measures of cystometric capacity and detrusor pressure.
Schurch summarized BoNTA published studies including
those with non-randomized designs for the neurogenic
and idiopathic OAB populations [19]. One result from
Schurch's review was a summary of the study specific suc-
cess rates stratified by the neurogenic and idiopathic pop-
ulations. Success in this instance was broadly based on the
proportion of patients who met a threshold of reduced
incontinence episodes.
The search of BoNTA studies yielded 165 abstracts for
review (Figure 1). A total of 11 articles met inclusion cri-
teria and an additional 17 articles were retrieved from
published reviews or references of accepted articles.
Sacral Neuromodulation (SNM)
Brazzelli and colleagues provided a review of SNM that
includes a discussion of outcomes used to demonstrate
the efficacy and safety as well as the success of the device
[20]. A more unified definition of success has been
reported within the SNM literature. Namely, the term
"cured" was equated to at least a 90% reduction in incon-
tinence symptoms and "improved" meant greater than a
50% reduction in incontinence symptoms. Together, a
"cured" or "improved" patient was thought to have suc-
ceeded on SNM. Other outcome measures such as pad
usage, incontinence severity, voiding frequency, urody-
namic parameters, and health-related quality of life were
reported to secondarily demonstrate efficacy, but not with
the same consistency as the cured or improved rates.
Safety outcomes mainly focused on adverse events such as
reoperations, replacement or relocation of the device, per-
manent explants, generator or electrode/lead failures,
pain, infection, wound problems, and adverse bowl func-
tion.BMC Urology 2009, 9:18 http://www.biomedcentral.com/1471-2490/9/18
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The search of SNM studies produced 86 abstracts for
review (Figure 1). From these, 4 articles were included and
7 studies came from references of review articles.
Augmentation Cystoplasty Surgery (AC)
Augmentation cystoplasty (AC) is a surgery where a seg-
ment of the bowel is removed and patched to the bisected
bladder. This method increases bladder capacity and
decreases bladder pressure caused by unstable contrac-
tions. Risks of this surgery include kidney or bladder infec-
tions, new recurrent UTIs, metabolic derangements,
mucus production, and in rare cases tumors within the
bladder. Khastgir et al. described outcomes measured for
augmentation cystoplasty [21]. The emphasized out-
comes were clinical outcomes (maximum detrusor pres-
sure and bladder volume capacity) and the quantification
of patient symptoms (incontinence episodes and number
of pads). Other outcomes included a questionnaire that
measured symptoms and disease specific quality of life,
and the evaluation of complications from the surgery. An
alternative to augmentation cystoplasty is detrusor myec-
tomy where an excision of the detrusor muscle from the
top of the bladder results in a bulge in the epithelium and
in turn increases storage capacity of the bladder. Although
this procedure is less risky, it is also thought to be less
effective. Similar outcomes emphasizing the clinical and
symptoms domains have been measured for detrusor
myectomy [22].
The search of AC studies produced 51 abstracts for review
(Figure 1). A total of 4 studies were included from the
search, 3 studies from references of review articles, and 2
studies from references of other accepted studies.
Summary overall interventions
Across BoNTA, SNM, and AC for OAB with UUI, 48 stud-
ies met the entry criteria for the review of treatment suc-
cess definitions (58.3% BoNTA, 22.9% SNM, and 18.8%
AC). Due to a small percentage of studies reporting more
than one definition of treatment success, the total number
of treatment success definitions was 52. Achieving com-
plete continence was reported as a definition of treatment
success 23 times (44%) (Table 1). Achieving at least a ≥
50% reduction in incontinence episodes (or other symp-
toms) was reported as a definition of treatment success 16
times (31%) (Table 2). Subjective patient satisfaction
measures were reported as a definition of treatment suc-
cess 13 times (25%) (Table 3). Achieving at least a ≥ 50%
reduction in incontinence episodes (or other symptoms)
was the most common definition for the idiopathic pop-
ulation (42%) whereas complete continence was the most
common definition for the neurogenic population
(59%). We now present supporting evidence for the ≥
Study search yield by intervention Figure 1
Study search yield by intervention.BMC Urology 2009, 9:18 http://www.biomedcentral.com/1471-2490/9/18
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50% reduction in incontinence episodes as a measure of
treatment success.
Treatment Success Association: ≥ 50% reduction in 
incontinence episodes
Of the 51 patients reporting incontinence scores at both
baseline and at six month visits across all treatment
groups in the Schurch et al trial, 25 (49%) achieved the ≥
50% reduction in incontinence episodes definition of
response. Patients with ≥ 50% reduction in incontinence
episodes on average had 8.8 higher I-QOL scores (95% CI:
-4.7, 22.3) and 0.07 higher SF-6D preference scores (95%
CI: 0.02, 0.12).
Table 1: Complete Continence: Treatment Success Definition by Intervention
Study Study Design Sample Size Study Population Comparator Success Evaluated 
(months)
Success %
Botulinum toxin type A
Kennelly, Top Spinal 
Cord Inj Rehabil, 2003 
[26]
Open Label 10 NOAB None 6 80
Reitz, Eur Urol, 2004 
[27]
Open Label 200 NOAB None 4 73
Giannantoni, J Urol, 2004 
[28]




Urol Nephrol, 2004 [29]
RCT 12 NOAB Intravesically 
Resiniferation
12 75.0
Klaphajone, Arch Phys 
Med Rehabil, 2005 [30]
Open Label 10 NOAB None 1.5 70
Schurch, J Urol, 2005 
[13]
RCT 38 NOAB Placebo 6 63
Kessler, Neurourol 
Urodynam, 2005* [31]
Open Label 11, 11 NOAB, IOAB None 3, 3 72, 91
Popat, J Urol, 2005* [32] Open Label 31, 44 NOAB, IOAB None 4, 4 55.2, 57
Werner, Am J Obstet 
Gynecol, 2005 [33]
Open Label 26 IOAB None 9 65
Kuo, J Urol, 2006* [34] Single Blind 35, 40 NOAB, IOAB None 3, 3 94, 73
Giannantoni, J Urol, 2006 
[35]
Open Label 23 NOAB None 3 78
Karsenty, Urol, 2006 
[36]
Open Label 17 NOAB None 5 100
Sahai, J Urol, 2007 [37] RCT 16 IOAB Placebo 3 50
Mascarenhas, Neurourol. 
Urodynam, 2008 [38]
Open label 21 NOAB None 2 42.8
Sacral neuromodulation
Bosch, J Urol, 2000 [39] Open Label 6 NOAB None 47 80
Chartier-Kastler, J Urol, 
2000 [40]
Open Label 9 NOAB None 43.6 67
Weil, Eur Urol, 2000 
[41]
RCT 21 IOAB Current Management 6 56




Open Label 17 NOAB None 75.6 70.5
Ivil, Int Urol Nephrol, 
2002 [44]
Open Label 17 IOAB None 11 83
Khastgir, Eur Urol, 2003 
[21]
Open Label 32 NOAB None 72 100
Quek, J Urol, 2003 [45] Open Label 26 NOAB None 96 69
Stoffel, Neurourol 
Urodynam, 2006 [46]
Open Label 12 NOAB None 20 88
* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations.
Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported.BMC Urology 2009, 9:18 http://www.biomedcentral.com/1471-2490/9/18
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Discussion
Deriving a definition of treatment success in any disease
area poses many challenges, but we argue that the benefits
outweigh the harms in undergoing such an exercise in
UUI OAB. Possible limitations to a definition of treat-
ment success in UUI OAB include: patient clinical hetero-
geneity (e.g. UUI OAB patients have varying levels of
incontinence), patient preference heterogeneity (e.g.
some patients having the same study outcomes may opt to
continue treatment whereas others may opt for alternative
interventions), and duration of treatment effect (e.g. if
incontinence or other symptoms are included in the
measure of success, then how often and over what time
period should they be measured?). At the population
level, a uniform treatment response outcome provides for
the comparison across various UUI OAB interventions,
gives researchers a clear and achievable target for purposes
of trial design, and allows payers to attain better value for
money on UUI OAB interventions for their insured popu-
lation.
Payne and Kelleher recently evaluated three possible treat-
ment response definitions that were informed from the
ICS definition of OAB: (i) a reduction by half or more in
all baseline symptoms (episodes of urgency, inconti-
nence, nocturia, and voiding frequency per 24 h); (ii) a
reduction by half or more in urgency and at least one
other symptom; or (iii) resolution of urgency episodes
and at least one other symptom [23]. All three treatment
response definitions were correlated with significant
changes in the King's Health Questionnaire. The authors
argued that clinical trials and the evidence base in OAB
focus on single endpoints such as incontinence episodes
or reduction in incontinence, but correctly point out that
the ICS definition of OAB mainly targets urgency and sec-
ondarily lists the other symptoms of incontinence, noctu-
ria, and increased voiding frequency. One of the main
pitfalls in using any of these three proposed treatment
response definitions is that there is yet to be a consensus
on how to measure urgency in a reliable and valid way
[24]. Further, if one is tasked to gather the current and
existing evidence across OAB interventions on treatment
Table 2: ≥ 50% Improvement in Incontinence Episodes or Other Symptoms: Treatment Success Definition by Intervention
Study Study Design Sample Size Study Population Comparator Success Evaluated 
(months)
Success %
Botulinum toxin type A
Flynn, J Urol, 2004 [47] Open Label 7 IOAB None 3 100
Kuo, Urology, 2004* [48] Open Label 12, 8 NOAB, IOAB None 3, 3 66.6, 75
Kuo, Urology, 2005 [49] Open Label 20 IOAB None 3 85
Kalsi, Eur Urol, 2006* 
[50]
Open Label 63, 38 NOAB, IOAB None 4, 4 86, 79
Kalsi, Ann Neurol, 2007 
[51]
Open Label 43 NOAB None 4 80
Mascarenhas, Neurourol. 
Urodynam, 2008 [38]
Open label 21 NOAB None 2 52.4
Sacral neuromodulation
Schmidt, J Urol, 1999 [52] RCT 34 IOAB Current Management 6 75
Bosch, J Urol, 2000 [39] Open Label 40 IOAB None 47 60
Amundsen, Am J Obstet 
Gynecol, 2002 [53]
Open Label 12 IOAB None 7 100
Bosch, J Urol, 2000 [39] Open Label 6 NOAB None 47 100
Hassouna, J Urol, 2000 
[54]
RCT 25 IOAB Current Management 6 56
Scheepens, Eur Urol, 
2003 [55]
Open Label 34 IOAB None 11 53
Van Voskuilen, BJU Int, 
2007 [56]
Open Label 31 IOAB None 15.5 90
Groenendijk, BJU Int, 
2008 [57]
Open Label 67 IOAB None 6 61
Wallace, Am J Obstet 
Gynecol, 2007 [58]
Open Label 33 NOAB None 12.5 84.8
Augmentation cystoplasty
Blaivas, J Urol, 2005 [59] Open Label 76 NOAB None 106.8 97
* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations.
Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported.BMC Urology 2009, 9:18 http://www.biomedcentral.com/1471-2490/9/18
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response, then retrospectively constructing a composite
definition of success is nearly impossible.
Taking into account the currently available evidence, the
most likely candidates for a definition of OAB with UUI
treatment success are measures that focus on reductions in
incontinence episodes. The achievement of full conti-
nence has been a common metric in BoNTA studies. But
in the case of a dichotomous outcome of success (yes/no),
full continence likely excludes many patients that are clin-
ically benefiting from treatment. The question then
becomes, what is an appropriate threshold in terms of
incontinence reduction that resonates as a clinically
meaningful improvement yet does not disregard too
many patients that are benefiting? We sought out a defini-
tion of success that limits misclassification/residual con-
founding by setting a threshold that most appropriately
includes those receiving meaningful clinical benefit while
excluding those that experience a measurable benefit that
is not clinically relevant.
We recommend that the appropriate threshold for defin-
ing OAB with UUI treatment success should be ≥ 50%
reduction in incontinence episodes from baseline. We
stress that the use of this definition may be sensitive to the
baseline incontinence rate and therefore, both the base-
line incontinence rate and the change in the rate should
be communicated in research findings. In part, the recom-
mendation definition is based on what is currently avail-
able and reported in the literature. The ≥ 50% reduction
in incontinence episodes treatment response definition
has been used across all reviewed intervention classes and
is associated with generic and disease specific HRQoL
measures. The average difference in the disease specific
HRQoL instrument, I-QOL, change scores was higher
than the minimal important difference (MID) reported
for stress urinary incontinence of 6.3 [17]. Although stress
urinary incontinence is not the study population, it is the
only known population wherein a MID for the I-QOL has
been reported. Additionally, Yalcin et al reported that
stress urinary incontinence patients appear to recognize
important clinical value at incontinence reductions of
approximately 50% [25]. If the MID for OAB with UUI
was found to be similar to that in stress urinary inconti-
nence, then the findings from the Schurch et al trial sug-
gest that the recommended treatment success definition is
associated with a meaningful improvement in a disease
specific HRQoL instrument.
There are several limitations to the study. The primary aim
of this research was to review the evidence on treatment
success definitions reported for OAB with UUI refractory
to oral antimuscarinics. We focused on three primary
intervention classes in order to make our literature search
Table 3: Subjective Improvement: Treatment Success Definition by Intervention
Study Study Design Sample Size Study Population Comparator Success Evaluated 
(months)
Success %
Botulinum toxin type A
Loch, Eur Urol Supp, 2003* 
[60]
Open Label 30, 30 NOAB, IOAB None 8, 8 67, 67
Rapp, Urology, 2004 [61] Open Label 35 IOAB None 6 60
Grosse, Eur Urol, 2005 [62] Open Label 66 NOAB None 10 86.3
Rajkumar, BJU Int, 2005 [63] Open Label 15 IOAB None 1.5 93
Schulte-Baukloh, Eur Urol, 
2005 [64]
Open Label 44 IOAB None 3 86
Schmid, J Urol, 2006 [65] Open Label 100 IOAB None 3 88
Schulte-Baukloh, Neur 
Urodyn, 2006 [66]
Open Label 16 NOAB None 6 100
Kuo, J Urol, 2007 [67] Open Label 45 IOAB None 3 80
Augmentation cystoplasty
Edlund, Scand J Urol Nephrol, 
2001 [68]
Open Label 25 IOAB None 60 78
Barrington, Int Urogynecol J, 
2006 [69]
Open Label 12 IOAB None 12 83
Chartier-Kaslter, Spinal Cord, 
2000 [43]
Open Label 17 NOAB None 75.6 88.5
Quek, J Urol, 2003 [45] Open Label 26 NOAB None 96 96
Nomura, Spinal Cord, 2002 
[70]
Open Label 11 NOAB None 66 100
* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations.
Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported.BMC Urology 2009, 9:18 http://www.biomedcentral.com/1471-2490/9/18
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tractable. By doing so, we did not summarize treatment
success definitions for more rare interventions in this pop-
ulation such as percutaneous tibial nerve stimulation
given the limited quantity of published evidence on such
interventions. We did not include behavior modification
interventions or antimuscarinics because of the antici-
pated large amount of patient characteristic heterogeneity
in this broad population. Increased heterogeneity in UUI
symptoms of a population could limit the generalizability
of a uniform treatment success definition. The association
of the recommended treatment success definition with
disease specific and generic HRQoL measures was per-
formed in a BoNTA compared to placebo trial of neuro-
genic incontinent patients. This same association may not
hold for open label studies or those with SNM or AC inter-
ventions. Although the recommended treatment success
definition of ≥ 50% reduction in incontinence episodes
from baseline was the most common observed definition
in the idiopathic OAB with UUI population, it should be
further validated against other OAB outcomes.
Conclusion
We echo arguments put forth by Payne and Kelleher on
the need for a standardized treatment success definition.
Moving forward, a success definition like those proposed
by Payne and Kelleher that includes many components of
the underlying symptoms of OAB (namely urgency)
makes clinical sense, but is currently not practical based
on difficulties in measuring urgency. Based on the current
evidence, we have proposed a definition of success for
OAB with UUI that is currently gaining momentum in the
literature and is supported by associations with clinically
meaningful outcomes. The adoption of the ≥ 50% reduc-
tion in incontinence episodes as the treatment response
definition for UUI OAB will provide for consistent and
valuable outcomes research for both clinical and health
economic applications.
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